CY1125060T1 - NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA REGULATORS - Google Patents
NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA REGULATORSInfo
- Publication number
- CY1125060T1 CY1125060T1 CY20221100197T CY221100197T CY1125060T1 CY 1125060 T1 CY1125060 T1 CY 1125060T1 CY 20221100197 T CY20221100197 T CY 20221100197T CY 221100197 T CY221100197 T CY 221100197T CY 1125060 T1 CY1125060 T1 CY 1125060T1
- Authority
- CY
- Cyprus
- Prior art keywords
- diseases
- ppar
- gamma
- regulators
- benzamide derivatives
- Prior art date
Links
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical class NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 title 1
- 102000000536 PPAR gamma Human genes 0.000 abstract 2
- 108010016731 PPAR gamma Proteins 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000023504 respiratory system disease Diseases 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/20—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/192—Radicals derived from carboxylic acids from aromatic carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Η παρούσα εφεύρεση αναφέρεται σε καινοτόμα παράγωγα του χημικού τύπου (Ι) ως ρυθμιστές των PPAR-γάμμα, σε διαδικασίες για τη παρασκευή τους, σε φαρμακευτικές συνθέσεις που περιέχουν τις εν λόγω ενώσεις και στην εν λόγω ένωση για χρήση της στη θεραπεία παθολογικών καταστάσεων, διαταραχών ή νοσημάτων που μπορούν να βελτιωθούν με ρύθμιση του PPAR-γάμμα υποδοχέα, όπως είναι ο καρκίνος, μεταβολικά νοσήματα, φλεγμονώδη νοσήματα, αναπνευστικά νοσήματα, αυτοάνοσα νοσήματα, νευροεκφυλιστικά νοσήματα, καρδιαγγειακά νοσήματα και νεφρικά νοσήματα.The present invention relates to novel derivatives of the chemical formula (I) as regulators of PPAR-gamma, to processes for their preparation, to pharmaceutical compositions containing said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can be improved by modulating the PPAR-gamma receptor, such as cancer, metabolic diseases, inflammatory diseases, respiratory diseases, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases and kidney diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17382845.0A EP3498694A1 (en) | 2017-12-12 | 2017-12-12 | New benzamide derivatives as ppar-gamma modulators |
| PCT/EP2018/084290 WO2019115498A1 (en) | 2017-12-12 | 2018-12-11 | New benzamide derivatives as ppar-gamma modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1125060T1 true CY1125060T1 (en) | 2023-06-09 |
Family
ID=60673764
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20221100197T CY1125060T1 (en) | 2017-12-12 | 2022-03-09 | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA REGULATORS |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US11267808B2 (en) |
| EP (2) | EP3498694A1 (en) |
| JP (1) | JP7212235B2 (en) |
| KR (1) | KR102688870B1 (en) |
| CN (1) | CN111630030B (en) |
| AU (1) | AU2018382461B2 (en) |
| BR (1) | BR112020011558A2 (en) |
| CA (1) | CA3084879A1 (en) |
| CY (1) | CY1125060T1 (en) |
| DK (1) | DK3724165T3 (en) |
| EA (1) | EA202091433A1 (en) |
| ES (1) | ES2908938T3 (en) |
| HR (1) | HRP20220329T1 (en) |
| HU (1) | HUE058004T2 (en) |
| LT (1) | LT3724165T (en) |
| MX (1) | MX2020006235A (en) |
| PL (1) | PL3724165T3 (en) |
| PT (1) | PT3724165T (en) |
| RS (1) | RS63021B1 (en) |
| SI (1) | SI3724165T1 (en) |
| WO (1) | WO2019115498A1 (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021092262A1 (en) * | 2019-11-05 | 2021-05-14 | Dermira, Inc. | Mrgprx2 antagonists and uses thereof |
| KR20230107291A (en) * | 2020-11-09 | 2023-07-14 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | PPARγ modulators and methods of use |
| CN113350346B (en) * | 2021-06-01 | 2023-06-27 | 广西医科大学第一附属医院 | Use of vincristine in preventing or treating myocardial fibrosis |
| AU2023231613A1 (en) * | 2022-03-08 | 2024-09-05 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
| WO2023172846A1 (en) * | 2022-03-08 | 2023-09-14 | Flare Therapeutics Inc. | Pparg inverse agonists and uses thereof |
| WO2023219879A1 (en) * | 2022-05-09 | 2023-11-16 | Eisai R&D Management Co., Ltd. | SOLID FORM OF PPAR-gamma MODULATORS AND METHODS OF USE |
| CN115160341B (en) * | 2022-07-18 | 2023-07-18 | 中国医学科学院医学实验动物研究所 | Benzoxazine compound and pharmaceutical application thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6022884A (en) | 1997-11-07 | 2000-02-08 | Amgen Inc. | Substituted pyridine compounds and methods of use |
| PL357678A1 (en) * | 2000-04-28 | 2004-07-26 | Sankyo Company, Limited | Ppargamma modulators |
| JP2003073357A (en) * | 2001-09-03 | 2003-03-12 | Mitsubishi Pharma Corp | Rho KINASE INHIBITOR COMPRISING AMIDE COMPOUND |
| US20080206194A1 (en) * | 2007-02-16 | 2008-08-28 | Glazer Robert I | Method for the treatment of breast cancer |
| US8686048B2 (en) * | 2010-05-06 | 2014-04-01 | Rhizen Pharmaceuticals Sa | Immunomodulator and anti-inflammatory compounds |
| CN104302627A (en) * | 2012-05-22 | 2015-01-21 | 北卡罗来纳大学教堂山分校 | Pyrimidine compounds for the treatment of cancer |
-
2017
- 2017-12-12 EP EP17382845.0A patent/EP3498694A1/en not_active Withdrawn
-
2018
- 2018-12-11 HU HUE18812195A patent/HUE058004T2/en unknown
- 2018-12-11 EP EP18812195.8A patent/EP3724165B1/en active Active
- 2018-12-11 RS RS20220183A patent/RS63021B1/en unknown
- 2018-12-11 MX MX2020006235A patent/MX2020006235A/en unknown
- 2018-12-11 KR KR1020207018762A patent/KR102688870B1/en active IP Right Grant
- 2018-12-11 BR BR112020011558-4A patent/BR112020011558A2/en unknown
- 2018-12-11 LT LTEPPCT/EP2018/084290T patent/LT3724165T/en unknown
- 2018-12-11 HR HRP20220329TT patent/HRP20220329T1/en unknown
- 2018-12-11 AU AU2018382461A patent/AU2018382461B2/en active Active
- 2018-12-11 EA EA202091433A patent/EA202091433A1/en unknown
- 2018-12-11 ES ES18812195T patent/ES2908938T3/en active Active
- 2018-12-11 DK DK18812195.8T patent/DK3724165T3/en active
- 2018-12-11 CN CN201880087036.4A patent/CN111630030B/en active Active
- 2018-12-11 US US16/771,514 patent/US11267808B2/en active Active
- 2018-12-11 JP JP2020532042A patent/JP7212235B2/en active Active
- 2018-12-11 PT PT188121958T patent/PT3724165T/en unknown
- 2018-12-11 CA CA3084879A patent/CA3084879A1/en active Pending
- 2018-12-11 PL PL18812195T patent/PL3724165T3/en unknown
- 2018-12-11 WO PCT/EP2018/084290 patent/WO2019115498A1/en unknown
- 2018-12-11 SI SI201830623T patent/SI3724165T1/en unknown
-
2022
- 2022-03-09 CY CY20221100197T patent/CY1125060T1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR102688870B1 (en) | 2024-07-25 |
| US20210171511A1 (en) | 2021-06-10 |
| EA202091433A1 (en) | 2020-09-09 |
| EP3724165B1 (en) | 2022-01-12 |
| RS63021B1 (en) | 2022-04-29 |
| JP7212235B2 (en) | 2023-01-25 |
| KR20200098557A (en) | 2020-08-20 |
| PL3724165T3 (en) | 2022-04-25 |
| EP3498694A1 (en) | 2019-06-19 |
| CN111630030B (en) | 2023-06-20 |
| PT3724165T (en) | 2022-04-06 |
| SI3724165T1 (en) | 2022-06-30 |
| MX2020006235A (en) | 2020-08-24 |
| JP2021505641A (en) | 2021-02-18 |
| DK3724165T3 (en) | 2022-02-21 |
| US11267808B2 (en) | 2022-03-08 |
| AU2018382461A1 (en) | 2020-07-09 |
| ES2908938T3 (en) | 2022-05-04 |
| LT3724165T (en) | 2022-03-25 |
| CN111630030A (en) | 2020-09-04 |
| BR112020011558A2 (en) | 2020-12-08 |
| CA3084879A1 (en) | 2019-06-20 |
| HRP20220329T1 (en) | 2022-05-13 |
| AU2018382461B2 (en) | 2023-04-27 |
| EP3724165A1 (en) | 2020-10-21 |
| HUE058004T2 (en) | 2022-06-28 |
| WO2019115498A1 (en) | 2019-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1125060T1 (en) | NEW BENZAMIDE DERIVATIVES AS PPAR-GAMMA REGULATORS | |
| CY1124918T1 (en) | CCR2 REGULATORS | |
| CY1124394T1 (en) | TETRAHYDROQUINOLINE COMPOSITIONS AS BET BROMO-SPECIAL INHIBITORS | |
| CY1124476T1 (en) | EGFR INHIBITOR, AND PREPARATION AND APPLICATION THEREOF | |
| CY1120969T1 (en) | CINOXALINE PRODUCTS USEFUL AS FGFR MODE MODIFIERS | |
| CY1124113T1 (en) | COMPOSITIONS AND METHODS FOR THE THERAPEUTIC TREATMENT OF CNS DISORDERS | |
| CY1122966T1 (en) | 5-BROMO-2,6-DI-(1H-PYRAZOL-1-YL)PYRIMIDIN-4-AMINE FOR USE IN THE THERAPEUTIC TREATMENT OF CANCER | |
| CY1124828T1 (en) | ALLOSTERIC MODULATORS OF NICOTINE ACETYLCHOLINE RECEPTORS | |
| CY1122652T1 (en) | SPIROCYCLIC COMPOUNDS AS INHIBITORS OF TRYPTOPHANE HYDROSYLASE | |
| EA201891620A1 (en) | INHIBITORS OF PROTEINKINASE 1, INTERACTIVATING WITH RECEPTOR | |
| EA201990189A1 (en) | SYNTHESIS OF N- (HETEROARYL) PYRROLO [3,2-D] PYRIMIDIN-2-AMINES | |
| EA201990187A1 (en) | PYRIMIDINE ANTIPROLIFERATION AGENTS | |
| CY1121395T1 (en) | TETRAHYDROPYRIDOPYRAZINES-FORMERS TOY GPR6 | |
| CO2020010465A2 (en) | Compounds for the treatment of kinase-dependent disorders | |
| EA201790492A1 (en) | CONNECTIONS THAT INHIBIT McL-1 PROTEIN | |
| EA201891344A1 (en) | NEW APONEL RECEPTOR AGONISTS AND APPLICATION METHODS | |
| EA201691725A1 (en) | CONNECTIONS FOR THE TREATMENT OF DISTRESSED MEDIATED DISTRIBUTIONS | |
| CY1123231T1 (en) | TETRAHYDROPYRIMIDODIAZEPINE AND TETRAHYDROPYRIDODIAZEPINE COMPOUNDS FOR THE TREATMENT OF PAIN AND PAIN-RELATED CONDITIONS | |
| EA201891336A1 (en) | Heteroarylhydroxypyrimidinones as agonists of the APJ receptor | |
| CY1125169T1 (en) | DIOL AMINOPYRAZINE COMPOUNDS AS PI3K-γ INHIBITORS | |
| CY1125150T1 (en) | PHENYL-2-HYDROXY-ACETYLAMINO-2-METHYL-PHENYL COMPOUNDS | |
| EA201691541A1 (en) | NEW ANTI-BAFF ANTIBODIES | |
| CY1124814T1 (en) | FUSED IMIDAZOLE DERIVATIVES SUBSTITUTED WITH TERTITAGENT HYDROXY GROUPS AS PI3K-GAMMA INHIBITORS | |
| EA202091803A1 (en) | TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GRELIN-O-ACYLTRANSFERASE (GOAT) INHIBITORS | |
| CY1124381T1 (en) | OXADIAZOLOPYRIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFER INHIBITORS |